NCT01725126 - To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 10, 2013

Primary Completion Date

September 12, 2013

Study Completion Date

September 12, 2013

Conditions

Obesity

Interventions

DRUG

GSK2890457

Provided as powder and capsule.

DRUG

Metformin

"Tablet~Part A: Single doses on Day 1 and Day 42 orally~Part B: Subject continues usual metformin dose through Run-in, and resumes after Treatment Period completed~Part C: Subject continues usual metformin dose throughout study"

DRUG

Placebo

Provided as powder and Capsule.

DRUG

Liraglutide

"Provided as Injection. 6mg/mL, 3mL injector pen that permits doses of 0.6mg, 1.2mg, and 1.8mg~Subcutaneous injection 18 weeks dosing (Stabilization and Treatment Periods, Part B only"

Trial Locations (3)

33169

GSK Investigational Site, Miami

66211

GSK Investigational Site, Overland Park

91910

GSK Investigational Site, Chula Vista